Table 2A.
Analytical evaluation of discrepant results (n = 49).
| Case | TMA Procleix |
RT-PCR Allplex™ |
Type of disagreement |
RT-PCR Alinity m |
Analytical result |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratioa | Ct |
Result | Ctc | |||||||
| Result | N | Result | E | RdRP | N | RdRP & N | ||||
| 1 | P | 4.18 | N | NA | NA | NA | Major | N | NA | N |
| 2 | N | NA | P | NA | NA | 37.59 | Major | NDd | – | ND |
| 3 | P | 3.92 | N | NA | NA | NA | Major | P | 40.99 | P |
| 4 | P | 3.81 | N | NA | NA | NA | Major | P | 39.53 | P |
| 5 | P | 3.81 | Ib | 37.96 | NA | NA | Minor | P | 40.94 | P |
| 6 | P | 4.00 | N | NA | NA | NA | Major | N | NA | N |
| 7 | P | 4.24 | N | NA | NA | NA | Major | N | NA | N |
| 8 | P | 4.24 | Ib | 38.02 | NA | NA | Minor | P | 40.03 | P |
| 9 | P | 4.18 | N | NA | NA | NA | Major | NDd | – | ND |
| 10 | P | 4.20 | Ib | 36.91 | NA | NA | Minor | NDd | – | ND |
| 11 | P | 3.73 | N | NA | NA | NA | Major | N | NA | N |
| 12 | P | 4.15 | N | NA | NA | NA | Major | P | 40.90 | P |
| 13 | P | 4.36 | N | NA | NA | NA | Major | P | 39.60 | P |
| 14 | P | 4.21 | N | NA | NA | NA | Major | P | 37.21 | P |
| 15 | P | 4.16 | N | NA | NA | NA | Major | P | 40.90 | P |
| 16 | P | 4.05 | Ib | 37.88 | NA | NA | Minor | NDd | – | ND |
| 17 | N | NA | P | NA | NA | 37.63 | Major | NDd | – | ND |
| 18 | P | 4.21 | N | NA | NA | NA | Major | N | NA | N |
| 19 | P | 4.23 | Ib | 38.06 | NA | NA | Minor | P | 40.99 | P |
| 20 | P | 4.50 | N | NA | NA | NA | Major | P | 40.99 | P |
| 21 | P | 4.46 | N | NA | NA | NA | Major | N | NA | N |
| 22 | P | 3.95 | N | NA | NA | NA | Major | N | NA | N |
| 23 | P | 3.97 | N | NA | NA | NA | Major | N | NA | N |
| 24 | P | 4.00 | N | NA | NA | NA | Major | N | NA | N |
| 25 | P | 4.12 | I | 38.23 | NA | NA | Minor | P | 40.99 | P |
| Case | TMA Procleix SARS-CoV-2 |
RT-PCR Allplex™ SARS-CoV-2 |
Type of disagreement | RT-PCR cobas® SARS-CoV-2 |
Analytical result | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Result | Ratioa | Result | Ct |
Result | Ct |
||||||
| N | E | RdRP | N | ORF-1ab | E | ||||||
| 26 | P | 4.17 | N | NA | NA | NA | Major | N | NA | NA | N |
| 27 | P | 3.78 | N | NA | NA | NA | Major | Ib | NA | 35.63 | Ib |
| 28 | P | 3.84 | N | NA | NA | NA | Major | Ib | NA | 37.73 | Ib |
| 29 | P | 4.16 | N | NA | NA | NA | Major | N | NA | NA | N |
| 30 | P | 3.93 | N | NA | NA | NA | Major | P | 32.4 | 34.98 | P |
| 31 | P | 3.90 | N | NA | NA | NA | Major | N | NA | NA | N |
| 32 | P | 4.22 | N | NA | NA | NA | Major | Ib | NA | 38.47 | Ib |
| 33 | P | 4.02 | N | NA | NA | NA | Major | N | NA | NA | N |
| 34 | P | 3.95 | N | NA | NA | NA | Major | N | NA | NA | N |
| 35 | P | 4.28 | N | NA | NA | NA | Major | P | 36.19 | 37.22 | P |
| 36 | P | 3.92 | Ib | 36.58 | NA | NA | Minor | P | 33.15 | 35.01 | P |
| 37 | P | 4.05 | N | NA | NA | NA | Major | N | NA | NA | N |
| 38 | P | 4.59 | Ib | 38.15 | NA | NA | Minor | P | 33.35 | 34.51 | P |
| 39 | P | 4.03 | N | NA | NA | NA | Major | N | NA | NA | N |
| 40 | P | 4.25 | N | NA | NA | NA | Major | Ib | NA | 38.01 | Ib |
| 41 | P | 4.22 | N | NA | NA | NA | Major | P | 35.58 | 35.87 | P |
| 42 | P | 3.99 | N | NA | NA | NA | Major | N | NA | NA | N |
| 43 | P | 3.84 | N | NA | NA | NA | Major | N | NA | NA | N |
| 44 | P | 4.04 | Ib | 38.18 | NA | NA | Minor | N | NA | NA | Ib |
| 45 | P | 4.46 | Ib | 38.26 | NA | NA | Minor | N | NA | NA | Ib |
| 46 | P | 4.04 | N | NA | NA | NA | Major | Ib | NA | 37.94 | Ib |
| 47 | P | 4.35 | N | NA | NA | NA | Major | P | 30.80 | 31.60 | P |
| 48 | P | 4.15 | Ib | 38.14 | NA | NA | Minor | N | NA | NA | Ib |
| 49 | P | 4.33 | N | NA | NA | NA | Major | N | NA | NA | N |
The ratio provided by the instrument corresponds to an analytical parameter based on chemiluminescense with a qualitative interpretation. Values ≥1.00 are considered reactive/positive, according to the manufacturer's criteria.
Inconclusive cases are considered: (i) those testing positive for the E target, but negative for both the N and the RdRP/S targets with the RT-PCR Allplex™ SARS-CoV-2 assay, according to the manufacturer's criteria, (ii) those testing positive for the E target, but negative for the ORF-1ab target with the RT-PCR cobas® SARS-CoV-2 assay, according to the manufacturer's criteria, and (iii) those unresolved after the discrepant analytical testing.
The two SARS-CoV-2-specific probes are labelled with the same fluorophore, so the test provides a unique Ct value for both RdRP and N targets.
Specimens unavailable for discrepant analytical testing.
A minor disagreement is considered that discrepancy testing positive with one assay but inconclusive with the other study technique. Contrary, a major disagreement is considered that reverting from positive to negative depending on the study assay.
Abbreviations: TMA: transcription-mediated amplification; RT-PCR: real-time reverse-transcriptase PCR; Ct: cycle-threshold; P: positive; N: negative; I: inconclusive; NA: not amplified; ND: not determined.